AIM

Invest in Bogota Honored as Top Investment Promotion Agency in Latin America and the Caribbean

Retrieved on: 
木曜日, 5月 9, 2024
USD, Investment, Corporation, AIM, Research, Development, Economic development, Quality of life, Growth, Drug

BOGOTÁ, Colombia, May 9, 2024 /PRNewswire/ -- The Corporation for the Development and Productivity of Bogota-Region, Invest in Bogota, has been awarded as the best investment promotion agency in Latin America and the Caribbean at the prestigious Annual Investment Meeting (AIM) event, the world's leading platform to discuss effective investment promotion strategies and facilitate opportunities for economic development, placed in Abu Dhabi.

Key Points: 
  • BOGOTÁ, Colombia, May 9, 2024 /PRNewswire/ -- The Corporation for the Development and Productivity of Bogota-Region, Invest in Bogota, has been awarded as the best investment promotion agency in Latin America and the Caribbean at the prestigious Annual Investment Meeting (AIM) event, the world's leading platform to discuss effective investment promotion strategies and facilitate opportunities for economic development, placed in Abu Dhabi.
  • During 2023, Invest in Bogota channeled significant foreign investments to mitigate the impact of the pandemic.
  • Foreign direct investment will be a catalyst for economic recovery, generating quality jobs and improving the quality of life in Bogota-Region.
  • Invest in Bogota reaffirms its commitment to driving socio-economic development, competitiveness, and internationalization, and positioning the city as the preferred destination for doing business in Latin America.

e-therapeutics plc shares now trading on JP Jenkins

Retrieved on: 
金曜日, 5月 10, 2024
RNA interference, Commercial, AIM, ETX, Galapagos NV, Automation, Appointment, Novo Nordisk, Companies House, Biology, Drug development, Drug discovery, Therapy, MASH, Pharmaceutical industry

JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.

Key Points: 
  • JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • The indicative pricing for the ordinary shares (ISIN: GB00B2823H99), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/e-therapeutics-plc/).
  • Veronika Oswald, Commercial Director of JP Jenkins said: “ETX’s transition from AIM to the JP Jenkins venue marks a pivotal milestone in our mission to enhance accessibility and liquidity for their shareholders and investors.

Caledonia Mining Corporation Plc Notice of Results and Investor Presentation 

Retrieved on: 
木曜日, 5月 9, 2024
AIM

ST HELIER, Jersey, May 09, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("Caledonia" or the "Company") (NYSE AMERICAN, AIM and VFEX: CMCL) expects to publish its Q1 results for 2024 on Monday, May 13, 2024.

Key Points: 
  • ST HELIER, Jersey, May 09, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("Caledonia" or the "Company") (NYSE AMERICAN, AIM and VFEX: CMCL) expects to publish its Q1 results for 2024 on Monday, May 13, 2024.
  • A remote presentation for analysts and investors will be held on the same day, at 2:00pm London time, followed by an opportunity to ask questions.
  • Register in advance for this webinar:
    After registering, you will receive a confirmation email containing information about joining the webinar.

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

Retrieved on: 
木曜日, 5月 9, 2024
Webcast, AIM, Doctor of Philosophy, Conference, Event

OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET.

Key Points: 
  • OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET.
  • The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer.
  • Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call.
  • The webcast will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com , and will be archived for 90 days following the live event.

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Retrieved on: 
木曜日, 5月 9, 2024
AREC, FDA, Insulin, Skin, Diabetes, AIM, Research, Patient, Liver, Physician, Absorption, Pharmaceutical industry

This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy.

Key Points: 
  • This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy.
  • Within the diabetes field more broadly we are seeing the rise of innovative delivery devices, including longer-wear and miniaturised pumps that are continually improving treatment options for patients.
  • This collaboration is one of many we hope to enable, to further enhance the benefits of these next-generation devices.”
    Gary Dulak, Senior Director, New Venture Programs Medtronic Diabetes, said: “Medtronic Diabetes is a pioneer in implantable insulin pump systems for people living with type 1 diabetes, who are unable to tolerate conventional therapy that delivers insulin subcutaneously (under the skin).
  • With intraperitoneal therapy via an implantable insulin pump system, insulin delivery is targeted for direct absorption by the liver via the implantable pump.

Notice of Results and Investor Presentation

Retrieved on: 
木曜日, 5月 9, 2024
Gold, AIM, Nasdaq Iceland

TORONTO, ONTARIO – May 9, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, will publish its Q1 2024 results on 14 May 2024.

Key Points: 
  • TORONTO, ONTARIO – May 9, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, will publish its Q1 2024 results on 14 May 2024.
  • A remote presentation for investors and analysts will be held on the same day, at 16:00 BST (15:00 GMT, 11:00 EST), followed by an opportunity to ask questions.
  • Details of how to join the presentation will be included in the announcement.

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on: 
水曜日, 5月 8, 2024
Hypoxemia, Supplement, Pulmonology, Patient, Adolescence, Inhalation, ATS, Euphoria, Adrenal insufficiency, Cystic fibrosis, Dizziness, AIM, Oxygen saturation (medicine), Doctor of Philosophy, Conference, Research, Bronchopulmonary dysplasia, Radiation-induced lung injury, Heart rate, Ageing, Transience, Headache, RIS, MRI, Magnetic resonance imaging, Hypoesthesia, Government, Asthma, Risk, COVID-19, Orthostatic hypertension, COPD, Medical imaging

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points: 
  • The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
  • The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
  • After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
  • Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.

Falcon Oil & Gas Ltd - TSX Venture Exchange Conditional Approval & Additional Subscription

Retrieved on: 
火曜日, 5月 7, 2024
Admission, AIM, TSX, TSX Venture Exchange, FOG, Indian stock exchange, Security (finance)

7 May 2024 - Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG), the international oil and gas company engaged in the exploration and development of unconventional oil and gas assets, is pleased to confirm that it has received TSX Venture Exchange conditional approval for the second tranche of the Subscription by Sheffield Holdings LP, as previously announced on 22 April 2024.

Key Points: 
  • 7 May 2024 - Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG), the international oil and gas company engaged in the exploration and development of unconventional oil and gas assets, is pleased to confirm that it has received TSX Venture Exchange conditional approval for the second tranche of the Subscription by Sheffield Holdings LP, as previously announced on 22 April 2024.
  • It is expected admission of the New Common Shares to trading on AIM will become effective and dealings in those New Common Shares will commence on AIM at 8.00a.m.
  • The New Common Shares will not trade on the TSX Venture Exchange Market until the date that is four months and a day after the day of issuance.
  • The Company’s total issued share capital following Admission will be 1,109,141,512 Common Shares.

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

Retrieved on: 
月曜日, 5月 6, 2024
CGMP, Rintatolimod, Immune system, AIM, Clinical trial, Cancer, Viral

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.

Key Points: 
  • OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies.
  • This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success.
  • Ampligen has had a series of clinical trial advances in 2024.

AIM Innovation Sessions from RealPage Move Multifamily Forward

Retrieved on: 
月曜日, 5月 6, 2024
Software, Construction & Property, Artificial Intelligence, Data Management, Technology, Other Construction & Property, Other Technology, Residential Building & Real Estate, Multimedia, Marketing, AIM, Lumina, Conference

RealPage, the leading global provider of AI-enabled software platforms to the real estate industry, is hosting three leadership sessions at the sold-out 2024 AIM (Apartment Innovation and Marketing) Conference® to spotlight value-building AI innovations and resident experience leadership sessions for multifamily property managers and their residents.

Key Points: 
  • RealPage, the leading global provider of AI-enabled software platforms to the real estate industry, is hosting three leadership sessions at the sold-out 2024 AIM (Apartment Innovation and Marketing) Conference® to spotlight value-building AI innovations and resident experience leadership sessions for multifamily property managers and their residents.
  • View the full release here: https://www.businesswire.com/news/home/20240506321089/en/
    RealPage is hosting three leadership sessions at the 2024 AIM Conference® to spotlight AI innovations and the resident experience.
  • May 6 & May 7, 2024
    Three sessions at the AIM Conference highlight the next generation of multifamily property operations with smarter systems that help build greater value at lower costs in a more efficient, engaging and responsive resident experience.
  • Marketing Master Class: Future-Proofing Multifamily: Navigating the Resident-Centric Revolution with Dayna Gardner (RealPage Industry Principal) and John M. Cashion, (Senior Practice Director, Head of Global Delivery at The Ritz-Carlton Leadership Center).